Key Takeaways
- • AEW Europe acquired a 10,900 sqm newly built, fully let life sciences asset in Gräfelfing, Munich, marking the firm's first German life sciences investment off-market from Aventin Real Estate.
- • The Grade A property features modern office and laboratory spaces across six stories with LEED Platinum certification, constructed between 2022–2024, and is fully leased to three international leading life sciences companies with a weighted average unexpired lease term (WAULT) of approximately 10 years.
- • The Munich asset is strategically positioned within one of Germany's and Europe's premier life sciences hubs, with more than 450 life sciences companies operating within a 4 km radius and 21% of the country's biotechnology firms based in the metropolitan area, including GSK, Biogen, MSD, Moderna, and Bristol-Myers Squibb.
- • The property includes strong sustainability infrastructure: photovoltaic installations, district heating, e-charging facilities, smart building systems, and excellent connectivity via the A95 and A96 motorways and S-Bahn rail access into Munich.
- • AEW Europe, managing €35.6 billion in European real estate assets as of September 2025, continues to build on existing investments in the life sciences sector, with this acquisition demonstrating institutional-grade asset positioning and long-term lease stability in a high-demand market segment.
Summary
AEW Europe, one of the world's largest real estate investment and asset managers, has completed an off-market acquisition of a newly constructed life sciences asset in Gräfelfing, Munich, representing the firm's inaugural investment in Germany's life sciences market. The 10,900 square meter Grade A property was acquired from Aventin Real Estate and constructed between 2022 and 2024 with modern, flexible office and laboratory spaces distributed across six floors. The asset has achieved LEED Platinum certification and incorporates advanced sustainability features including photovoltaic installations, district heating systems, e-charging infrastructure, and smart building technology.
The acquisition represents a strategic entry into one of Continental Europe's most significant life sciences clusters. The Munich metropolitan area hosts over 450 life sciences companies within a 4 kilometer radius of the asset, accounting for approximately 21% of Germany's total biotechnology sector. Major multinational occupants in the region include GSK, Biogen, MSD, Moderna, and Bristol-Myers Squibb. The location benefits from proximity to world-class research institutions including Ludwig Maximilians-Universität München and the Max-Planck Institute of Biochemistry, as well as the Innovation Centre of Biotechnology.
The property's investment fundamentals demonstrate institutional-grade quality. It is fully let to three international leading life sciences companies with a weighted average unexpired lease term of approximately 10 years, providing stable, long-duration cash flows. Transportation connectivity is excellent, with direct access to the A95 and A96 motorways and S-Bahn rail service into Munich's central business district. According to Jeffrey King, Senior Fund Manager at AEW Europe, this acquisition builds on the firm's existing life sciences investments in Denmark and demonstrates continued expansion within the sector across Continental Europe. As of September 30, 2025, AEW Europe managed €35.6 billion of real estate assets across Europe on behalf of funds and separate accounts, positioning this transaction within a broader institutional investment platform focused on Grade A, fully leased assets in high-demand markets.
The acquisition represents a strategic entry into one of Continental Europe's most significant life sciences clusters. The Munich metropolitan area hosts over 450 life sciences companies within a 4 kilometer radius of the asset, accounting for approximately 21% of Germany's total biotechnology sector. Major multinational occupants in the region include GSK, Biogen, MSD, Moderna, and Bristol-Myers Squibb. The location benefits from proximity to world-class research institutions including Ludwig Maximilians-Universität München and the Max-Planck Institute of Biochemistry, as well as the Innovation Centre of Biotechnology.
The property's investment fundamentals demonstrate institutional-grade quality. It is fully let to three international leading life sciences companies with a weighted average unexpired lease term of approximately 10 years, providing stable, long-duration cash flows. Transportation connectivity is excellent, with direct access to the A95 and A96 motorways and S-Bahn rail service into Munich's central business district. According to Jeffrey King, Senior Fund Manager at AEW Europe, this acquisition builds on the firm's existing life sciences investments in Denmark and demonstrates continued expansion within the sector across Continental Europe. As of September 30, 2025, AEW Europe managed €35.6 billion of real estate assets across Europe on behalf of funds and separate accounts, positioning this transaction within a broader institutional investment platform focused on Grade A, fully leased assets in high-demand markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.